ISSN 1662-4009 (online)

ey0019.15-1 | Obesity | ESPEYB19

15.1. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes

JP Frias , MJ Davies , J Rosenstock , FC Perez Manghi , L Fernandez Lando , BK Bergman , B Liu , X Cui , K Brown , SURPASS-2 Investigators

N Engl J Med. 2021;385(6):503-15. doi: 10.1056/NEJMoa2107519.PubMed ID: 34170647Brief summary: this randomized control trial in 1879 adults with type 2 diabetes compared effects of once-weekly Tirzepatide (5, 10 or 15 mg) versus once-weekly Semaglutide (1 mg) on glycemic control. After 40 weeks, all doses of Tirzepatide were superior to Semaglutide on lowering HbA1c.Gluca...